The objective of this review is to assess the benefits and harms of methotrexate for patients with giant cell arteritis in terms of the following major outcomes: disease relapse, sustained discontinuation of corticosteroids, cumulative dose of glucocorticoids, cranial ischemic complications, health-related quality of life, short term serious adverse effects, and withdrawals due to adverse events.